| Drug Type Prophylactic vaccine, mRNA vaccine | 
| Synonyms bivalent second generation mRNA Vaccine (CureVac), CV2CoV-beta/delta, CV2CoV.351+CV2CoV.617.2 | 
| Target | 
| Action modulators | 
| Mechanism SARS-CoV-2 S protein modulators(SARS-CoV-2 S protein modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| COVID-19 | Preclinical | Germany  | - | |
| COVID-19 | Preclinical | Germany  | - | 





